Zambon heading to US market with €500m a...Zambon is set to acquire respiratory company Breath Therapeutics for up to €500m to complement its respiratory pipeline and get access to the US market. more ➔
Gut microbiome boosts muscle strengthSwedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle. more ➔
3P Pharma finds new major investor Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing … more ➔
Curetis lower respiratory tract panel read...Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections. more ➔
Merck and Broad Institute announce CRISPR... Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing. more ➔
Billions for the circular economyTogether with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy. more ➔
Genmab launches US$502m IPODanish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline. more ➔
AM-Pharma raises €116m for Phase IIIDutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III. more ➔
US$5bn deal for GalapagosBelgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform. more ➔
Boehringer snaps up cancer vaccine develop... German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics. more ➔
